BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 11119395)

  • 1. The positive predictive value of cervical smears in previously screened postmenopausal women: the Heart and Estrogen/progestin Replacement Study (HERS).
    Sawaya GF; Grady D; Kerlikowske K; Valleur JL; Barnabei VM; Bass K; Snyder TE; Pickar JH; Agarwal SK; Mandelblatt J
    Ann Intern Med; 2000 Dec; 133(12):942-50. PubMed ID: 11119395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of cervical cytological abnormalities with aging in the women's health initiative: a randomized controlled trial.
    Yasmeen S; Romano PS; Pettinger M; Johnson SR; Hubbell FA; Lane DS; Hendrix SL
    Obstet Gynecol; 2006 Aug; 108(2):410-9. PubMed ID: 16880313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen plus progestin and risk of venous thrombosis.
    Cushman M; Kuller LH; Prentice R; Rodabough RJ; Psaty BM; Stafford RS; Sidney S; Rosendaal FR;
    JAMA; 2004 Oct; 292(13):1573-80. PubMed ID: 15467059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
    Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
    JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
    Shumaker SA; Legault C; Rapp SR; Thal L; Wallace RB; Ockene JK; Hendrix SL; Jones BN; Assaf AR; Jackson RD; Kotchen JM; Wassertheil-Smoller S; Wactawski-Wende J;
    JAMA; 2003 May; 289(20):2651-62. PubMed ID: 12771112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
    Rapp SR; Espeland MA; Shumaker SA; Henderson VW; Brunner RL; Manson JE; Gass ML; Stefanick ML; Lane DS; Hays J; Johnson KC; Coker LH; Dailey M; Bowen D;
    JAMA; 2003 May; 289(20):2663-72. PubMed ID: 12771113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.
    Hulley S; Grady D; Bush T; Furberg C; Herrington D; Riggs B; Vittinghoff E
    JAMA; 1998 Aug; 280(7):605-13. PubMed ID: 9718051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.
    Anderson GL; Judd HL; Kaunitz AM; Barad DH; Beresford SA; Pettinger M; Liu J; McNeeley SG; Lopez AM;
    JAMA; 2003 Oct; 290(13):1739-48. PubMed ID: 14519708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial.
    Toh S; Hernández-Díaz S; Logan R; Rossouw JE; Hernán MA
    Ann Intern Med; 2010 Feb; 152(4):211-7. PubMed ID: 20157135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.
    Chlebowski RT; Anderson GL; Gass M; Lane DS; Aragaki AK; Kuller LH; Manson JE; Stefanick ML; Ockene J; Sarto GE; Johnson KC; Wactawski-Wende J; Ravdin PM; Schenken R; Hendrix SL; Rajkovic A; Rohan TE; Yasmeen S; Prentice RL;
    JAMA; 2010 Oct; 304(15):1684-92. PubMed ID: 20959578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of atypical glandular cells of undetermined significance.
    Geier CS; Wilson M; Creasman W
    Am J Obstet Gynecol; 2001 Jan; 184(2):64-9. PubMed ID: 11174481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study.
    Grady D; Wenger NK; Herrington D; Khan S; Furberg C; Hunninghake D; Vittinghoff E; Hulley S
    Ann Intern Med; 2000 May; 132(9):689-96. PubMed ID: 10787361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytohormonal and morphological alterations in cervicovaginal smears of postmenopausal women on hormone replacement therapy.
    Gupta S; Kumar N; Singhal N; Manektala U; Jain S; Sodhani P
    Diagn Cytopathol; 2006 Oct; 34(10):676-81. PubMed ID: 16955474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.
    Chlebowski RT; Anderson GL; Sarto GE; Haque R; Runowicz CD; Aragaki AK; Thomson CA; Howard BV; Wactawski-Wende J; Chen C; Rohan TE; Simon MS; Reed SD; Manson JE
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26668177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
    Rossouw JE; Anderson GL; Prentice RL; LaCroix AZ; Kooperberg C; Stefanick ML; Jackson RD; Beresford SA; Howard BV; Johnson KC; Kotchen JM; Ockene J;
    JAMA; 2002 Jul; 288(3):321-33. PubMed ID: 12117397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.
    Chlebowski RT; Hendrix SL; Langer RD; Stefanick ML; Gass M; Lane D; Rodabough RJ; Gilligan MA; Cyr MG; Thomson CA; Khandekar J; Petrovitch H; McTiernan A;
    JAMA; 2003 Jun; 289(24):3243-53. PubMed ID: 12824205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of estrogen therapy on gallbladder disease.
    Cirillo DJ; Wallace RB; Rodabough RJ; Greenland P; LaCroix AZ; Limacher MC; Larson JC
    JAMA; 2005 Jan; 293(3):330-9. PubMed ID: 15657326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.
    Maalouf NM; Sato AH; Welch BJ; Howard BV; Cochrane BB; Sakhaee K; Robbins JA
    Arch Intern Med; 2010 Oct; 170(18):1678-85. PubMed ID: 20937929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
    Hulley S; Furberg C; Barrett-Connor E; Cauley J; Grady D; Haskell W; Knopp R; Lowery M; Satterfield S; Schrott H; Vittinghoff E; Hunninghake D;
    JAMA; 2002 Jul; 288(1):58-66. PubMed ID: 12090863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.